TY - JOUR T1 - Omicron: a drug developer's perspective. AU - Fang,Fang Flora, AU - Shi,Pei-Yong, PY - 2021/12/25/pubmed PY - 2022/1/18/medline PY - 2021/12/24/entrez KW - COVID19 KW - COVID19drugs KW - COVID19vaccines KW - Omicron variants KW - SARS-CoV-2 SP - 208 EP - 211 JF - Emerging microbes & infections JO - Emerg Microbes Infect VL - 11 IS - 1 N2 - We performed an annotation of 35 mutations in the spike protein of the SARS-CoV-2 Omicron variant. Our analysis of the mutations indicates that Omicron has gained prominent immune evasion and potential for enhanced transmissibility. Previous modeling study has revealed that continued evolution in both immune evasion and enhanced transmissibility by SARS-CoV-2 would compromise vaccines as tools for the pandemic control. To combat the future variants of SARS-CoV-2, the world needs novel antiviral drugs that are effective at curb viral spreading without introducing additional selective pressure towards resistant variants. SN - 2222-1751 UR - https://www.unboundmedicine.com/medline/citation/34951568/Omicron:_a_drug_developer's_perspective_ L2 - https://www.tandfonline.com/doi/full/10.1080/22221751.2021.2023330 DB - PRIME DP - Unbound Medicine ER -